Local aromatase activity alterations in breast cancer tissues: A potential way of decision support for clinicians

被引:0
作者
Tuzuner, Mete Bora [1 ]
Ozturk, Tulin [2 ]
Ilvan, Sennur [2 ]
Turna, Hande [3 ]
Yurdun, Turkan [4 ]
Yilmaz-Aydogan, Hulya [5 ]
Ozturk, Oguz [5 ]
机构
[1] Acibadem Labmed Med Labs, Ctr Res & Dev, Icerenkoy Mah,Kerem Aydinlar Kampusu, TR-34752 Atasehir, Turkey
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Dept Pathol, Koca Mustafapasa Cd 53 D 53, TR-34096 Fatih Istanbul, Turkey
[3] Istanbul Univ Cerrahpasa, Cerrahpasa Med Sch, Sect Med Oncol, Dept Internal Med, Koca Mustafapasa Cd 53 D 53, TR-34096 Fatih Istanbul, Turkey
[4] Marmara Univ, Dept Pharmaceut Toxicol, Fac Pharm, Tibbiye Cad 49, TR-34668 Istanbul, Turkey
[5] Istanbul Univ, Aziz Sancar Inst Expt Med, Dept Mol Med, Vakif Gureba Cad Capa Kampusu Sehremini, TR-34390 Fatih Istanbul, Turkey
关键词
Breast cancer; Tumor microenvironment; Aromatase; Estrogens; Mass spectrometry;
D O I
10.1016/j.yexmp.2020.104574
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background and aims: It is becoming evident that local estrogen exposure is important in postmenopausal breast cancer patients. The microenvironment is established by breast stromal cells based on communication with tumor cells that is essential to cancer development, invasion, and metastasis. Here we investigated aromatase activity levels in both tumor and matched stromal tissues by showing their impact on the manufacturing of local estrogen and tumor progression in cases of invasive ductal carcinoma (IDC). Methods: Tumor (T) and tumor-associated stroma (TAS) neighboring tissues were acquired from each postmenopausal patient, diagnosed with IDC, and categorized as luminal A (n = 20). The control group was formed from tumor-free breast tissue samples (N, n = 12). A microsomal-based technique was created to compare breast tissue aromatase activities using liquid chromatography - mass spectrometry. Findings: We observed that the TAS tissues have the highest aromatase activities (p < 0.05). High progesterone receptor (PR) intensity levels were found to be decreasing the activity level in these tissues significantly (p < 0.05). Tumor tissue specific aromatase activity levels of postmenopausal patients' were tend to be lower compared to healthy premenopausal subjects' (3 fold, p < 0.001). In addition low activity in tumor tissues were associated with low grade and late stage cancers. Conclusions: Early detection and personalized therapy is essential for postmenopausal breast cancer patients. Together, our in-house tandem mass spectrometry technique has the potential for further development and standardization for the measurement of aromatase activity and may assist clinicians decide on therapy policies for postmenopausal IDC patients which could be an invaluable asset for precise and specific evaluation.
引用
收藏
页数:9
相关论文
共 36 条
  • [1] Regulation of Aromatase Expression in Breast Cancer Tissue
    Bulun, S. E.
    Lin, Z.
    Zhao, H.
    Lu, M.
    Amin, S.
    Reierstad, S.
    Chen, D.
    [J]. STEROID ENZYMES AND CANCER, 2009, 1155 : 121 - 131
  • [2] Regulation of aromatase expression in estrogen-responsive breast and uterine disease: From bench to treatment
    Bulun, SE
    Lin, ZH
    Imir, G
    Amin, S
    Demura, M
    Yilmaz, B
    Martin, R
    Utsunomiya, H
    Thung, S
    Gurates, B
    Tamura, M
    Langoi, D
    Deb, S
    [J]. PHARMACOLOGICAL REVIEWS, 2005, 57 (03) : 359 - 383
  • [3] Cavalieri E, 2000, J Natl Cancer Inst Monogr, P75
  • [4] Weight gain increases human aromatase expression in mammary gland
    Chen, Dong
    Zhao, Hong
    Coon, John S., V
    Ono, Masanori
    Pearson, Elizabeth K.
    Bulun, Serdar E.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2012, 355 (01) : 114 - 120
  • [5] Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression
    Cirri, Paolo
    Chiarugi, Paola
    [J]. CANCER AND METASTASIS REVIEWS, 2012, 31 (1-2) : 195 - 208
  • [6] Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Cui, XJ
    Schiff, R
    Arpino, G
    Osborne, CK
    Lee, AV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7721 - 7735
  • [7] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
    Dowsett, Mitch
    Cuzick, Jack
    Ingle, Jim
    Coates, Alan
    Forbes, John
    Bliss, Judith
    Buyse, Marc
    Baum, Michael
    Buzdar, Aman
    Colleoni, Marco
    Coombes, Charles
    Snowdon, Claire
    Gnant, Michael
    Jakesz, Raimund
    Kaufmann, Manfred
    Boccardo, Francesco
    Godwin, Jon
    Davies, Christina
    Peto, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 509 - 518
  • [8] Early Breast Cancer Trialists Collaborative Group, 2005, LANCET, V365, P1687, DOI 10.1016/S0140-6736(05)66544-0
  • [9] Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
    Ferlay, J.
    Colombet, M.
    Soerjomataram, I.
    Mathers, C.
    Parkin, D. M.
    Pineros, M.
    Znaor, A.
    Bray, F.
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (08) : 1941 - 1953
  • [10] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674